This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Actelion Pharmaceuticals Ltd.
Drug Names(s): Clearazide, Mechlorethamine gel, Nitrogen Mustard, Valchlor Gel 0.016%, Chlormethine, Ledaga (EU)
Description: Clearazide is a topically delivered form of nitrogen mustard, an alkylating agent that works by suppressing T-cell proliferation thereby reducing or clearing skin lesions associated with CTCL. It works by binding to DNA, crosslinking two strands and preventing cell duplication. It binds to the N7 nitrogen on the DNA base guanine.
In January 2012, Yaupon Therapeutics announced it changed its name to Ceptaris Therapeutics.
Ceptaris and Actelion
In July 2013, Actelion and Ceptaris entered into an Agreement for Actelion to acquire Ceptaris. Under the terms of the Merger Agreement, Actelion paid to Ceptaris USD 25 million upon signing and will pay to Ceptaris' shareholders USD 225 million upon closing of the transaction. Ceptaris' shareholders are also eligible to receive additional payments based on net sales of VALCHLOR and/or the achievement of certain commercial milestones.
In September 2013, Actelion announced that it has concluded the acquisition of Ceptaris following US Food and Drug Administration (FDA) approval for Valchlor (mechlorethamine) gel 0.016% for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy.
Additional information available to subscribers only: